文献速递骨软组织肉瘤与黑色素瘤消化系统肿瘤

MTH1抑制剂治疗癌症的验证与开发

Validation and development of MTH1 inhibitors for treatment of cancer.
PubMed 文献 · Ann Oncol · 2016-11-08

该研究在体外用MTH1抑制剂或siRNA/shRNA敲低MTH1处理人癌细胞系,并在BRAF V600E突变恶性黑色素瘤患者来源异种移植及人结肠癌SW480、HCT116异种移植模型中探索MTH1抑制对肿瘤生长的影响,发现不能杀死癌细胞的MTH1抑制剂也不能将氧化核苷酸引入DNA,并描述新型MTH1抑制剂TH1579(Karonudib)为最佳同类MTH1抑制剂。

要点

  • 不能杀死癌细胞的MTH1抑制剂也不能将毒性氧化核苷酸引入DNA。
  • TH1579(Karonudib)是TH588类似物,为强效选择性MTH1抑制剂,口服利用度好。
  • TH1579在体内展示良好的药代动力学和抗癌特性。

核心结论

  • MTH1抑制剂必须将氧化核苷酸引入DNA才能杀死癌细胞。
  • TH1579被描述为最佳同类MTH1抑制剂,预期有助于进一步验证MTH1抑制剂概念。

研究设计与样本

  • 人癌细胞系体外暴露于MTH1抑制剂或用siRNA或shRNA敲低MTH1。
  • 在BRAF V600E突变恶性黑色素瘤患者来源异种移植及人结肠癌SW480和HCT116异种移植模型中探索MTH1抑制对肿瘤生长的影响。

主要发现

  • 近期描述的不能杀死癌细胞的MTH1抑制剂也不能将毒性氧化核苷酸引入DNA。
  • TH1579是TH588的类似物,为强效选择性MTH1抑制剂,口服利用度好,在体内展示良好的药代动力学和抗癌特性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previously, we showed cancer cells rely on the MTH1 protein to prevent incorporation of otherwise deadly oxidised nucleotides into DNA and we developed MTH1 inhibitors which selectively kill cancer cells. Recently, several new and potent inhibitors of MTH1 were demonstrated to be non-toxic to cancer cells, challenging the utility of MTH1 inhibition as a target for cancer treatment. MATERIAL AND METHODS: Human cancer cell lines were exposed in vitro to MTH1 inhibitors or depleted of MTH1 by siRNA or shRNA. 8-oxodG was measured by immunostaining and modified comet assay. Thermal Proteome profiling, proteomics, cellular thermal shift assays, kinase and CEREP panel were used for target engagement, mode of action and selectivity investigations of MTH1 inhibitors. Effect of MTH1 inhibition on tumour growth was explored in BRAF V600E-mutated malignant melanoma patient derived xenograft and human colon cancer SW480 and HCT116 xenograft models. RESULTS: Here, we demonstrate that recently described MTH1 inhibitors, which fail to kill cancer cells, also fail to introduce the toxic oxidized nucleotides into DNA. We also describe a new MTH1 inhibitor TH1579, (Karonudib), an analogue of TH588, which is a potent, selective MTH1 inhibitor with good oral availability and demonstrates excellent pharmacokinetic and anti-cancer properties in vivo. CONCLUSION: We demonstrate that in order to kill cancer cells MTH1 inhibitors must also introduce oxidized nucleotides into DNA. Furthermore, we describe TH1579 as a best-in-class MTH1 inhibitor, which we expect to be useful in order to further validate the MTH1 inhibitor concept.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Warpman Berglund U, Sanjiv K, Gad H, et al. Validation and development of MTH1 inhibitors for treatment of cancer. Ann Oncol. 2016. PMID: 27827301. doi:10.1093/annonc/mdw429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。